- Molecular Biomarkers for Early Assessment of Cancer Risk
-
Stars at Night Ballroom B1‚ Convention Center
Chair: Udayan Apte, University of Kansas Medical Center
Co-Chair: Connie Mitchell, HESI
Primary Endorser: Carcinogenesis Specialty Section
Endorser(s): Molecular and Systems Biology Specialty Section
Endorser(s): Regulatory and Safety Evaluation Specialty SectionTraditional two-year rodent bioassays for evaluating carcinogenicity of chemicals and pharmaceuticals have long served as the regulatory standard; however, these studies are resource-intensive, time-consuming, and rely on apical endpoints that occur late in the disease process. Tumor formation represents the culmination of a cascade of earlier molecular and cellular events, including DNA damage, altered signaling pathways, and sustained proliferative responses. By the time these pathological changes are detectable, critical mechanistic information that could inform earlier decision-making has already been missed. Advances in genomics and molecular toxicology have enabled the identification of biomarkers that reflect molecular initiating events (MIEs) and early key events in carcinogenesis. These genomic biomarkers, measurable in short-term in vivo or in vitro studies, provide a mechanistically anchored approach to detect perturbations associated with cancer development well before tumor formation. When integrated into a weight-of-evidence framework, such tools offer the potential to more efficiently prioritize compounds, inform dose selection, and identify hazards without the need for prolonged exposure studies. There is increasing recognition across regulatory agencies, academia, and industry that genomic biomarkers can play a transformative role in carcinogenicity assessment for industrial chemicals, agrochemicals, and pharmaceuticals. Their application aligns with global efforts to modernize toxicology by incorporating mechanistic data, improving human relevance, and reducing reliance on long-term animal testing. As regulatory frameworks evolve to incorporate new approach methodologies (NAMs), the validation and application of genomic biomarkers represent a critical step toward more predictive, efficient, and ethical cancer risk assessment strategies. This session will highlight recent advances in the development and application of genomic biomarkers for early cancer risk assessment, with a focus on their use in short-term studies to inform carcinogenic potential. The session will start with a brief introduction to frame the scientific and regulatory context, including current challenges associated with traditional carcinogenicity testing and the opportunity for mechanistically informed approaches. One talk will highlight the use of gene expression biomarkers to predict genotoxicity, including their development, validation, and application within integrated testing strategies. Another presentation will focus on emerging genomic biomarkers linked to key molecular initiating events in carcinogenesis, demonstrating how these tools can be used to detect pathway perturbations relevant to tumor development. A third talk will present advances in error-corrected sequencing technologies, emphasizing their ability to sensitively detect rare mutations and quantify early genetic changes associated with cancer risk. The session will conclude with a panel discussion to engage speakers and the audience on the opportunities and challenges associated with implementing genomic biomarkers in regulatory decision-making, including considerations for validation, standardization, and integration into weight-of-evidence frameworks.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
